B. Laperche, Stratégie d'innovation des firmes des sciences de la vie et appropriation des ressources végétales. Mondes en développement, pp.109-122, 2009.
DOI : 10.3917/med.147.0109

B. Laperche, Stratégie d'innovation des firmes des sciences de la vie et appropriation des ressources végétales, Mondes en développement, pp.81-107, 2010.
DOI : 10.3917/med.147.0109

B. Coriat and F. Orsi, Brevets pharmaceutiques, génériques et santé publique, 2003.

A. M. Turing, Computing machinery and intelligence. Mind, pp.433-460, 1950.
DOI : 10.1007/978-1-4020-6710-5_3

B. Bouzy, Intelligence artificielle : introduction

J. Lettvin, What the Frog's Eye Tells the Frog's Brain, Proceedings of the IRE, pp.47-58, 1959.
DOI : 10.1109/JRPROC.1959.287207

«. Ai, healthcare and the future of drug pricing, p.2017

W. D. Arnold, What doctor? Why AI and robotics will define new health

«. Ims and P. Centricity, IMSCG global industry-wide survey with 70 respondents drawn from large, medium, and small pharmaceutical and biotech manufacturers in the US and EU. Respondents represented senior marketing, research, and access related roles, 2016.

. Regnier, S « Introduction to Health Economics and Pricing », ESCP Europe Lecture, 2016.

. Regnier, https://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/uc m513027.pdf consulté le 24 novembre 2017 à 8h47 43. http://roivant.com/roivant-sciences-launches-datavant-improve-clinical-trials-artificialintelligence, Innovation in the pharmaceutical industry, 201642-04.